JAK2/Src Inhibitor NS-018

Known as: NS-018 
An orally bioavailable, small molecule inhibitor of Janus-associated kinase 2 (JAK2) and Src-family kinases, with potential antineoplastic activity… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
012320112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
NS-018 is a Janus-activated kinase 2 (JAK2)-selective inhibitor, targeting the JAK–signal transducer and activator of… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Review
2017
Review
2017
Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the centerpiece of therapy… (More)
  • table 1
Is this relevant?
Review
2017
Review
2017
INTRODUCTION Since the discovery of the activating V617F mutation in Janus kinase 2 (JAK2), a number of pharmacologic inhibitors… (More)
Is this relevant?
2014
2014
A single somatic mutation, V617F, in Janus kinase 2 (JAK2) is one of the causes of myeloproliferative neoplasms (MPNs), including… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2014
2014
JAK2/STAT signaling promotes survival and expansion of myelodysplastic syndrome (MDS) clones, but little is known about the… (More)
Is this relevant?
Review
2014
Review
2014
INTRODUCTION Disordered signaling through the JAK/STAT pathway is a hallmark of myeloproliferative neoplasms (MPNs). Targeted… (More)
Is this relevant?
Review
2013
Review
2013
INTRODUCTION Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to… (More)
Is this relevant?
Review
2012
Review
2012
JAK-STAT (Janus associated kinase-signal transducer and activator of transcription) pathway plays a critical role in transduction… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
2011
2011
Aberrant activation of Janus kinase 2 (JAK2) caused by somatic mutation of JAK2 (JAK2V617F) or the thrombopoietin receptor… (More)
Is this relevant?